Allergy Shots for Pollen: Candidacy Decision Aid and Treatment Options
Yes — allergy shots target pollen by formulating SCIT against the specific tree, grass, and weed pollens to which a patient's IgE is sensitized, and pollen is the allergen category with the deepest RCT base in immunotherapy. This page is a three-step candidacy decision aid: is pollen actually driving symptoms, is SCIT versus an FDA-approved SLIT tablet the right tool, and what is the realistic outcome? Cochrane Calderón 2007: symptom SMD −0.73 across 51 RCTs.
7 peer-reviewed sources
Yes, allergy shots work for pollen. SCIT targets specific tree, grass, and weed pollens confirmed by IgE testing. Cox 2011 indicates SCIT when pharmacotherapy fails and sensitization is documented. FDA-approved SLIT tablets also exist for grass and ragweed.
The essentials
Allergy shots for pollen are subcutaneous immunotherapy (SCIT) formulated against the specific tree, grass, and weed pollens to which a patient's IgE testing demonstrates sensitization. This page is structured as a three-step decision aid for patients asking "should I get allergy shots for pollen?"
Step 1: Is pollen actually driving the symptoms? Pollen-allergic patients typically have predictable seasonal AR symptom calendars: spring sneezing and congestion during tree-pollen season, worsening in late spring/summer during grass season, and a second fall peak during ragweed season. A patient with year-round nasal symptoms that worsen in all seasons more likely has a dust mite or pet dander overlay in addition to pollens. Distinguishing the seasonal pattern from a perennial one matters because it shapes extract content and sets realistic expectations. IgE testing — either a blood panel or skin prick test — is the appropriate diagnostic step before any immunotherapy decision.
Curex pairs at-home IgE testing with board-certified allergist review to identify which specific pollens are driving a given patient's seasonal symptoms — directing whether pollen-SCIT, an FDA-approved SLIT tablet, or at-home SCIT shots is the right candidate.
Step 2: Is SCIT or SLIT the right tool? Cox 2011 PP3 defines the indication threshold: subcutaneous or sublingual immunotherapy is considered when symptoms persist or worsen despite avoidance and pharmacotherapy, and when IgE sensitization is documented. For some pollen allergens, an FDA-approved SLIT tablet is a direct alternative to SCIT injections: Grastek (timothy grass, ALK, ages 5–65), Oralair (5-grass mix, Stallergenes, ages 5–65), and Ragwitek (short ragweed, Merck, ages 5–65 after 2021 expansion). These are daily sublingual tablets requiring only one supervised first-dose clinic visit. For tree pollens (birch, oak, alder) and most weeds other than ragweed, no FDA-approved SLIT tablet exists in the US — SCIT is the route. The choice between FDA SLIT tablets and SCIT should be made with a board-certified allergist who can map the patient's sensitization profile to available options. For eligible patients choosing SCIT, Curex's at-home allergy shot kit ($129/month) delivers the same personalized extract — compounded to USP <797> — as one weekly self-administered injection, with first-dose Zoom supervision and allergist oversight.
Step 3: What is the realistic outcome? Walker 2001 JACI documented approximately 49% symptom-score reduction and approximately 80% medication-score reduction versus placebo in a grass SCIT RCT (P=.007). Creticos 1996 NEJM documented significant symptom and peak-flow improvement during ragweed season. Bødtger 2002 Allergy documented approximately 40% symptom and 50% medication reduction for birch SCIT. Durham 1999 NEJM showed grass SCIT delivered 3 additional years of clinical remission after a 3–4 year course. The climate-change context: ragweed season has lengthened across Eastern US (Ziska et al.), making the 3–12 year post-course remission (Durham 1999) an increasingly compelling argument for starting sooner.
A caution about the "yearly pollen shot": a single intramuscular Kenalog-40 or Depo-Medrol injection is a depot corticosteroid, not immunotherapy. It delivers symptomatic relief for 1–3 weeks per FDA label. The AAAAI/ACAAI rhinitis Practice Parameter discourages it and contraindicates recurrent administration due to HPA-axis suppression. This is not an alternative to SCIT; it is a different product class with different indications, risks, and outcomes.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Pollen-specific efficacy benchmarks from landmark RCTs provide the quantitative basis for candidacy counseling.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
How do I know if my symptoms are from pollen or something else?
Pollen-driven allergic rhinitis follows predictable seasonal patterns correlated with local pollen calendars: spring eye itching and sneezing during tree season (March–May in most of the Northeast), worsening with grass season (May–July), and a second fall peak during ragweed season (August–October east of the Rockies). Year-round symptoms — particularly morning nasal congestion worse on waking or perennial sneezing with no seasonal variation — more commonly suggest dust mite or pet dander. A serum-specific IgE panel or skin prick test by a board-certified allergist is the definitive diagnostic step. Guessing at the trigger without IgE data risks an immunotherapy vial targeting the wrong allergen.
What is the Cox 2011 indication threshold for pollen allergy shots?
Cox L et al. (J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55) state that subcutaneous or sublingual immunotherapy should be considered when symptoms persist or worsen despite adequate avoidance and pharmacotherapy and when IgE sensitization to a clinically relevant allergen is documented. In practice: moderate-to-severe seasonal AR that is not controlled by a second-generation antihistamine plus intranasal corticosteroid in a patient with a positive skin prick test or serum-specific IgE to the implicated pollen, typically over two consecutive pollen seasons. Duration and severity of symptoms together define the "adequate pharmacotherapy trial" standard.
What is the difference between pollen SCIT and FDA-approved SLIT tablets?
SCIT (allergy shots) delivers allergen extract by subcutaneous injection and can be formulated for any pollen allergen using standardized or non-standardized extracts. Traditionally administered in-clinic with a 30-minute post-injection observation period, SCIT is now also available at home through programs like Curex's at-home shot kit ($129/month) — a personalized compounded serum (USP <797>) self-administered weekly, with the first dose and every dose change supervised live over Zoom by the prescribing allergist and a prescribed epinephrine auto-injector confirmed on hand. FDA-approved SLIT tablets (Grastek for timothy grass, Oralair for 5-grass, Ragwitek for short ragweed) are daily sublingual tablets taken at home after one supervised first-dose clinic visit; they are FDA-regulated products with specific formulations, approved ages (5–65), and boxed warnings for anaphylaxis. Both SCIT and SLIT tablets are disease-modifying and require 3–5 years of treatment. SLIT tablets cover only specific allergens; SCIT can cover the full sensitization profile including tree pollens and weeds with no FDA-approved tablet counterpart.
Can pollen allergy shots prevent asthma in children?
The pediatric PAT study (Möller C et al., J Allergy Clin Immunol 2002;109:251-256; Jacobsen L et al., Allergy 2007;62:943-948) randomized 205 children with seasonal allergic rhinitis and no asthma to SCIT or open control. At 10-year follow-up, 16 of 64 SCIT-treated children had developed asthma versus 24 of 53 controls, yielding an adjusted OR of 4.6 (95% CI 1.5–13.7) favoring asthma-free status in the SCIT group. This is the strongest disease-prevention argument in all of allergy medicine. No pharmacotherapy produces a comparable asthma-prevention effect. This benefit applies to pediatric patients; asthma prevention data from adult-onset pollen SCIT are not established.
Do pollen allergy shots work for oak and hickory tree allergies?
SCIT can be formulated for oak and hickory pollen using non-standardized extracts, though the RCT evidence base for non-birch tree pollens is substantially smaller than for birch, grass, and ragweed. Oak, hickory, maple, and hornbeam share IgE cross-reactivity with birch via the PR-10 / Bet v 1 protein family, so a patient who is sensitized to birch and oak via this cross-reactivity may see benefit from birch SCIT alone. Component-resolved testing (Bet v 1 ImmunoCAP) can clarify whether a "tree-allergic" patient's IgE is primarily birch-driven or represents independent sensitizations to additional species.
What are the realistic side effects of pollen allergy shots?
Local reactions at the injection site — redness, itching, swelling — occur in approximately 78–82% of patients at some point during a course and approximately 16% of individual injections per the Calabria/Tankersley LOCAL study (JACI 2009). Large local reactions (greater than 25mm, persisting beyond 24 hours) occur at approximately 0.4% of injections. Systemic reactions — sneezing, urticaria, asthma — occur at approximately 0.1% of injections and in 1.9% of patients (Epstein 2014). Fatal anaphylaxis is very rare: 1 fatality per 23.3 million injection visits, 2008–2012. Approximately 70% of systemic reactions occur within 30 minutes of injection — which is why Curex requires a prescribed epinephrine auto-injector on hand before your first dose and supervises your first injection and every dose change live over Zoom. For at-home maintenance doses, observe yourself for 30 minutes and contact your care team immediately if symptoms arise.
How long do pollen allergy shots work after stopping treatment?
Durham SR et al. (N Engl J Med 1999;341:468-475) documented at least 3 years of sustained clinical benefit after stopping a 3–4 year grass SCIT course, with persistent allergen-specific IgG4. Real-world data suggest benefit lasting 3–12 years post-treatment for patients who completed the full course. Benefits are more durable in patients who complete 3–5 years versus shorter courses — the 2-year GRASS trial found shorter courses insufficient to establish durable immunological memory. The pediatric PAT study (Jacobsen 2007) confirmed asthma-prevention benefits at 10-year follow-up.
Related Articles
Bee Allergy Shots (Venom Immunotherapy) | Curex Guide
Bee allergy shots are venom immunotherapy (VIT) — NOT environmental SCIT. Cochrane Boyle 2012: 2.7% vs 39.8% systemic reaction on re-sting. 5 FDA venoms. Must be in-office.
Read moreAre There Seasonal Allergy Shots? Yes — 3 Types | Curex
Yes — seasonal allergy shots exist as SCIT, SLIT tablets, or depot steroid. Curex at-home SCIT ($129/mo) covers tree, grass, and weed pollen.
Read moreCat Allergy Vaccine Explained | Curex SCIT Guide
Cat allergy vaccine means three different things. SCIT uses FDA-standardized Fel d 1 extract for ~72% symptom relief. No one-shot cure exists.
Read moreWhere To Get Allergy Shots | Curex Allergy Shot Guide
Get allergy shots at an allergist office or at home with Curex SCIT ($129/mo). HOPD sites can bill $24,400 for what a freestanding clinic charges $1,827.
Read moreAllergy Shot for Pollen: Mono vs Poly Guide | Curex
An allergy shot for pollen targets your specific IgE-sensitized pollen. True monosensitization is rarer than expected — most patients react to 3+ pollens. Guide inside.
Read moreAllergy Shots vs Drops: Evidence-Based Comparison | Curex
Allergy shots (SCIT) vs sublingual drops (SLIT): comparable efficacy per Nelson 2015, but SLIT has zero fatalities vs 1 per 2.5M shots. Full comparison.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.